Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- GTX23380 - Provider product page
- Provider
- GeneTex
- Proper citation
- GeneTex Cat#GTX23380, RRID:AB_379784
- Product name
- ABCG2 antibody [BXP-21]
- Antibody type
- Monoclonal
- Reactivity
- Human
- Host
- Mouse
Submitted references Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.
A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier.
ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.
Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer.
Zhang YK, Wang YJ, Lei ZN, Zhang GN, Zhang XY, Wang DS, Al-Rihani SB, Shukla S, Ambudkar SV, Kaddoumi A, Shi Z, Chen ZS
Cancer letters 2019 Feb 1;442:104-112
Cancer letters 2019 Feb 1;442:104-112
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Zhang GN, Zhang YK, Wang YJ, Gupta P, Ashby CR Jr, Alqahtani S, Deng T, Bates SE, Kaddoumi A, Wurpel JND, Lei YX, Chen ZS
Cancer letters 2018 Jun 28;424:19-29
Cancer letters 2018 Jun 28;424:19-29
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
Zhang GN, Zhang YK, Wang YJ, Barbuti AM, Zhu XJ, Yu XY, Wen AW, Wurpel JND, Chen ZS
Pharmacological research 2017 May;119:89-98
Pharmacological research 2017 May;119:89-98
Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.
Zhang YK, Zhang GN, Wang YJ, Patel BA, Talele TT, Yang DH, Chen ZS
Scientific reports 2016 May 9;6:25694
Scientific reports 2016 May 9;6:25694
A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier.
Kim DG, Bynoe MS
The Journal of clinical investigation 2016 May 2;126(5):1717-33
The Journal of clinical investigation 2016 May 2;126(5):1717-33
ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.
Trumpi K, Emmink BL, Prins AM, van Oijen MG, van Diest PJ, Punt CJ, Koopman M, Kranenburg O, Rinkes IH
Journal of Cancer 2015;6(11):1079-86
Journal of Cancer 2015;6(11):1079-86
Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
Yamasaki T, Fujinaga M, Kawamura K, Hatori A, Yui J, Nengaki N, Ogawa M, Yoshida Y, Wakizaka H, Yanamoto K, Fukumura T, Zhang MR
Nuclear medicine and biology 2011 Jul;38(5):707-14
Nuclear medicine and biology 2011 Jul;38(5):707-14
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer.
Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y
Cancer 2010 Jan 15;116(2):302-8
Cancer 2010 Jan 15;116(2):302-8
No comments: Submit comment
No validations: Submit validation data